| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 72,413 | 39,730 | 20,876 | 4,933 |
| Research and development | 75,947 | 49,735 | 30,744 | 15,066 |
| General and administrative | 4,277 | 4,598 | 5,067 | 4,342 |
| Total operating expenses | 80,224 | 54,333 | 35,811 | 19,408 |
| Operating loss | -7,811 | -14,603 | -14,935 | -14,475 |
| Interest income | 302 | 310 | 437 | 1,022 |
| Non-cash interest expense related to sale of future royalties | 608 | 672 | 997 | 631 |
| Other income (expense), net | -7 | -1 | -1 | 22 |
| Loss before income taxes | -8,124 | -14,966 | -15,496 | -14,062 |
| Provision for income taxes | 17 | 20 | 95 | 18 |
| Net loss | -8,141 | -14,986 | -15,591 | -14,080 |
| Unrealized gain (loss) on available-for-sale investments, net of tax | 5 | 0 | -11 | 43 |
| Comprehensive loss | -8,136 | -14,986 | -15,602 | -14,037 |
| Net loss per share - basic and diluted (in dollars per share) | -0.04 | -0.07 | -0.07 | -0.06 |
| Shares used to compute net loss per share - basic and diluted (in shares) | 228,926,340 | 228,367,812 | 227,923,636 | 227,452,883 |
Vaxart, Inc. (VXRT)
Vaxart, Inc. (VXRT)